syndrome provoked by Shiga toxins [7] . They show that Shiga toxins are internalized by red blood cells and then released in microvesicles. It is these toxin-containing microvesicles that participate in the prothrombotic lesions, hemolysis, and transfer of the toxin from the circulation into the kidney, that are characteristic of this deadly syndrome. Furthermore, a research article from the groups of Lee and Park describes for the first time the apoptotic processes induced by Shiga toxins in human retinal pigment epithelial cells, suggesting the mechanisms leading to blindness in severe cases of hemolytic and uremic syndrome [8] . Gal et al. extend their characterization of the crucial role of inflammation in ricin toxin pathogenesis by showing that total body irradiation of mice decreases inflammation markers and extends time to death [9] . Second after ricin toxin, the plant RIP abrin is considered an increasing risk of malevolent and suicidal use. Thus, there is a need for detection and decontamination tools. Tam et al. set up a two-monoclonal antibody-based ELISA that can detect as low as 1 ng/mL of abrin and that shows no false positive detection of other plant RIPs [10] . The same team showed that while various pH treatments of the toxin did not affect its activity, heating above 74 • C completely inactivated its capacity to kill cells and mice. However, they showed that this treatment affects the lectin part of the toxin rather than its catalytic chain [11] . Interestingly, this article sets a correspondence between cytotoxicity testing and the mouse bioassay, which should help reduce the use of the mouse model for the evaluation of abrin and other RIPs.
Due to sporadic but recurrent cases of biosuicide and biothreats with ricin toxin, there is an urgent need for a treatment of human intoxication. The group of Kronman gives us a thorough review of existing data on potential countermeasures and treatment strategies, although none are approved for medical use [12] . While antibodies represent the most realistic approach in the case of early post-intoxication intervention, the review stresses the importance of not only eliminating the toxin but also downregulating the explosive inflammatory response triggered by the toxin, as additionally described in a research article by the same group [9] .
Interestingly, Whitfield and colleagues describe in detail an F(ab') 2 polyclonal ovine antitoxin and its performance in a mouse model of ricin inhalation that is intended to be pharmaceutically qualified for human use [13] . Protection is mediated both by reducing the amount of circulating toxin and blocking its intracellular trafficking to the Golgi apparatus.
Many studies in the past showed that a fraction only of the antibodies generated in the course of an immune response against ricin toxin was neutralizing. Here, the group of Nicholas Mantis identifies the presence of a supercluster of neutralizing epitopes at the interface between the A and B chains of the toxin by analyzing a series of V H H camelid antibody fragments from a phage library generated against ricin toxin [14] . Interestingly, these antibodies do not interfere with the binding of the toxin to the galactose and N-acetyl-galactosamine residues of cell surface glycosylation. This is a step forward in understanding the basis for antibody-mediated protection against this toxin.
Hall et al. review the attempts to develop antibodies or other antitoxin strategies to treat the hemolytic and uremic syndrome caused by Shiga toxins, none of which have reached approval [15] . They suggest that the rarity of this disease is a major limit to achieving the necessary clinical trials. Then they advocate the development of drugs targeting the unfolded protein response and the ribotoxic stress response triggered by Shiga toxins as these pathways are involved in many other conditions, which may decrease the barriers to commercial development.
The final aspect of research on RIPs covered by this Special Issue concerns their use in the engineering of immunotoxins to target cancer or cells infected by Human immunodeficiency virus (HIV) by conjugation of antibodies or other targeting moieties. Two reviews by Fabbrini et al. and Rust et al. discuss the difficulties that have been encountered in the development of several generations of immunotoxins, none of which have been approved after clinical trials [1, 16] . They also present the future trends of immunotoxin development. Two examples of the complexities of such development are given in the articles of Polito et al. and Au et al. The former analyzes the difference in the mechanism of killing of two closely related saporin-containing immunotoxins targeting different markers on B-cell lymphomas, CD20 and CD22 [17] . The latter addresses the effect of PEGylation on the pharmacology, biological activity, and antibody induction of a TAT-maize RIP construction designed to target HIV-infected cells [18] .
Overall, this Special Issue of Toxins presents the most recent data on all aspects of RIPs, including function, diversity, evolution, as well as mechanism, pathophysiology, medical countermeasures, and engineering into anticancer drugs.
